Research output per year
Research output per year
Research output
- 3 Article
Search results
-
2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
CALM Study Group, Nov 2022, In: The Lancet Haematology. 9, 11, p. e833-e843Research output: Contribution to journal › Article › peer-review
57 Citations (Scopus) -
2021
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
Fattizzo, B., Ireland, R., Dunlop, A., Yallop, D., Kassam, S., Large, J., Gandhi, S., Muus, P., Manogaran, C., Sanchez, K., Consonni, D., Barcellini, W., Mufti, G. J., Marsh, J. C. W. & Kulasekararaj, A. G., Nov 2021, In: Leukemia. 35, 11, p. 3223-3231 9 p.Research output: Contribution to journal › Article › peer-review
Open Access45 Citations (Scopus) -
2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
UCART19 Group, 12 Dec 2020, In: The Lancet. 396, 10266, p. 1885-1894 10 p.Research output: Contribution to journal › Article › peer-review
232 Citations (Scopus)